Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $6.2 million.

  • Arcutis Biotherapeutics' Treasury Shares fell 459.25% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 459.25%. This contributed to the annual value of $6.1 million for FY2024, which is 10668.63% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Treasury Shares stood at $6.2 million for Q3 2025, which was down 459.25% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Treasury Shares peaked at $7.2 million during Q1 2025, and registered a low of $310068.0 during Q1 2021.
  • Moreover, its 5-year median value for Treasury Shares was $2.9 million (2023), whereas its average is $3.4 million.
  • In the last 5 years, Arcutis Biotherapeutics' Treasury Shares soared by 37033.05% in 2022 and then plummeted by 459.25% in 2025.
  • Arcutis Biotherapeutics' Treasury Shares (Quarter) stood at $335196.0 in 2021, then soared by 370.33% to $1.6 million in 2022, then skyrocketed by 85.83% to $2.9 million in 2023, then soared by 106.69% to $6.1 million in 2024, then grew by 2.23% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $6.6 million for Q2 2025, and $7.2 million during Q1 2025.